Modified antisense nucleotides complementary to a section of the human Ha-ras gene

The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnorma...

Full description

Saved in:
Bibliographic Details
Main Authors PEYMAN ANUSCHIRWAN, PIROLLO KATHLEEN, UHLMANN EUGEN, WILL DAVID WILLIAM, RAIT ANTONINA, CHANG ESTHER
Format Patent
LanguageEnglish
Published 20.04.2004
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy. The modified oligodeoxynucleotide according to the invention has the sequence 5'-TxAxTxTxCxCxGxTxCxAxT-3'-O-PO2-O-R (SEQ ID NO:1), wherein X is an internucleotide linkage of type o or s, with the proviso that x is an s linkage at least 4 times and at most 9 times, and o means a phosphodiester internucleoside linkage, s means a phosphorothioate internucleoside linkage, R means a C8-C21 alkyl group, -(CH2-CH2O)n-(CH2)m-CH3, or -CH2-CH(OH)CH2O-(CH2)q-CH3 wherein n is an integer from 1 to 6, m is an integer from 0 to 20 and q is an integer from 7 to 20 and A is 2'-deoxyadenosine, G is 2'-deoxyguanosine, C is 2'-deoxycytidine and T is thymidine.
Bibliography:Application Number: US20000423198